Global Veterinary Healthcare to Reach USD 63.6B by 2031

By Ken Research

The global veterinary healthcare market covers medicines, vaccines, parasiticides, diagnostics, specialty products, and related technologies used across companion and production animals. According to Ken Research, the market was valued at USD 44,300 million in 2025 and is projected to reach USD 63,555 million by 2031. The Global Veterinary Healthcare Market report models a 6.2% CAGR for 2026-2031, with growth increasingly tied to prevention, chronic care, diagnostics, and digital monitoring. This mix supports recurring demand across diverse animal-health settings.

The central commercial shift is from broad, episodic treatment toward prevention and evidence-led care. Companion-animal medicalization supports specialty therapies, while livestock biosecurity sustains vaccination and rapid testing. The counter-risk is structural: affordability, disease volatility, antimicrobial controls, regulatory review, and cold-chain execution can slow adoption. Suppliers combining differentiated products with diagnostics, veterinary workflows, and reliable distribution should outperform commodity-focused portfolios.

Market Definition and Evidence Snapshot

Veterinary healthcare here includes products and technologies used to prevent, diagnose, monitor, and treat disease across companion animals, livestock, poultry, aquaculture, clinics, farms, and laboratories. The market is becoming more prevention-led, diagnostics-intensive, and technology-enabled, with growth increasingly shaped by product mix and clinical value rather than treatment volume alone.

• 2025 base value: USD 44,300 million, with North America the largest commercial region.
• 2031 forecast: USD 63,555 million at a 6.2% CAGR during 2026-2031.
• Segment structure: product type is the dominant dimension; therapeutics are the largest revenue pool, while technology is fastest growing.
• Official signal: the World Organisation for Animal Health reported a 5% decline in antimicrobial use between 2020 and 2022 across data covering 71% of global animal biomass.
• Commercial implication: prevention, diagnostics, and digital monitoring should capture more incremental value, while undifferentiated anti-infectives face stewardship and pricing pressure.

Ken Research's Global Animal Health Market provides context on pharmaceuticals, vaccines, diagnostics, and demand across species.

Growth Mechanisms and Market Economics

Market expansion is not simply a function of more animals receiving treatment. Ken Research separates treatment and diagnostic volume from price and mix, showing that value growth also comes from specialty therapies, biologics, testing, and prevention. The strongest revenue pools therefore depend increasingly on clinical differentiation, repeat use, and veterinary-workflow integration.

What is expanding the companion-animal demand base?

Longer treatment duration and willingness to fund chronic care are raising revenue per companion animal. Specialty conditions can generate repeat diagnostics and medication use. Companion animals represented 55.5% of modeled market revenue in 2025. The Global Pet Care Market adds context on the spending ecosystem supporting this demand.

Why is prevention gaining economic importance?

Vaccines, parasiticides, biosecurity, and surveillance create scheduled demand while reducing outbreak losses. This is especially valuable in poultry, swine, cattle, and aquaculture, where disease can disrupt production and trade. The WOAH 2025 animal-health report highlights vaccination across high-priority diseases, reinforcing prevention as both a health and continuity tool.

How do diagnostics change the revenue model?

Rapid and molecular diagnostics improve treatment selection and antimicrobial stewardship while creating recurring reagent, laboratory, software, and monitoring revenue. Ken Research models diagnostics and digital solutions at 11.2% of market value in 2025. The Europe Veterinary Healthcare Market also shows diagnostics outpacing the broader regional market.

Where Market Value Is Moving

Incremental value is moving toward preventive biologics, specialty companion-animal medicines, molecular testing, and connected monitoring rather than replacing therapeutics outright. Product type remains the main segmentation lens, while technology changes faster. Buyers increasingly reward solutions that shorten response time, improve treatment precision, or protect recurring production economics.

Which segment remains largest?

Therapeutics remain the largest product-type revenue pool because treatment demand spans infectious, parasitic, chronic, and reproductive conditions. However, mature anti-infectives offer less differentiation than specialty medicines, vaccines, and diagnostics. Indonesia's Animal Health and Veterinary Care Market illustrates the gradual move from reactive treatment toward preventive protocols and higher diagnostic intensity.

Which segment is growing fastest?

Technology is the fastest-growing segmentation dimension, with digital monitoring and precision delivery identified as the strongest-expanding area. Continuous data can identify disease earlier, improve timing, and connect diagnostics with product recommendations. The GCC Animal Health Market provides a regional example of rapid diagnostics, digitization, and prevention supporting higher-value supplier models.

Competition, Regulation and Entry Barriers

Competition is shaped by portfolio breadth, regulatory dossiers, diagnostics, distribution, technical service, and veterinary relationships. The report identifies Zoetis, Merck Animal Health, Boehringer Ingelheim Animal Health, Elanco, IDEXX, Ceva, Virbac, Dechra, Vetoquinol, and Phibro as important participants, but does not provide dependable share percentages for ranking them here.

What creates durable competitive advantage?

Differentiated products matter most when supported by evidence and channel execution. Specialty therapeutics depend on diagnosis, veterinarian confidence, and adherence; vaccines depend on registration and cold-chain integrity. Integrated product and diagnostic ecosystems can capture more customer value, while local technical support remains important.

How is antimicrobial stewardship changing portfolios?

Antimicrobial controls raise the value of vaccination, diagnostics, husbandry, and targeted treatment. WOAH urges stronger prevention and surveillance, while FAO identifies misuse in livestock and aquaculture as a resistance risk. Anti-infective demand remains, but the standard for responsible use is higher and more precise intervention gains value.

What is the strongest entry risk?

The main barrier is execution across regulation, affordability, and distribution. Biological products require dependable temperature control, and product registration can delay launches. The Saudi Arabia Animal Health Market shows how cold-chain validation, import exposure, registration, and local technical service can shape competitiveness.

Explore the complete Global Veterinary Healthcare Market analysis for full segmentation, regional comparison, competitive coverage, and forecast detail.

Decision Framework and Market Outlook

The base case is continued mid-single-digit expansion supported by higher prevention, specialty-care, and diagnostic intensity. The decision is where suppliers should place capital to capture durable value. Strong positions combine clinical differentiation, repeatable demand, regulatory readiness, and distribution capable of serving both premium clinics and production-animal customers.

Decision Framework

Executives should translate the evidence into exactly three actions:

• Prioritize recurring care pools: focus resources on vaccines, parasiticides, chronic-care therapeutics, diagnostics, and monitoring where repeat use improves revenue visibility.
• Build route-to-market resilience: strengthen cold chains, distributor incentives, veterinarian education, and laboratory or clinic integration before geographic expansion.
• Measure portfolio quality: track diagnostic attachment, adherence, prevention mix, species concentration, regulatory cycle time, and margin resilience rather than growth alone.

Signals to Monitor

The base case strengthens if vaccination coverage, diagnostic intensity, chronic care, and formal veterinary access rise faster than expected. It weakens if affordability pressure, registration delays, disease disruption, or weak cold chains constrain uptake. Leading indicators through 2031 include prevention mix, diagnostics and digital share, companion-animal revenue share, antimicrobial policy, regional access, and treatment-volume growth.

For a market-specific strategy discussion, talk to Ken Research about portfolio prioritization, market entry, and demand validation.

Frequently Asked Questions

Executive questions center on scope, data status, forecast consistency, segmentation, and execution risk. The answers below use the report's 2025 base year and 2026-2031 forecast period, distinguish estimates from completed facts, and focus on the product, technology, opportunity, and risk signals most relevant to market-entry, portfolio, and investment decisions.

What does the global veterinary healthcare market include?

The market includes veterinary medicines, vaccines, parasiticides, diagnostics, specialty products, and related technologies used to prevent, identify, monitor, and treat animal disease. It covers companion and production animals across clinics, farms, laboratories, and other animal-health settings. The scope focuses on monetized veterinary healthcare rather than unrelated pet-consumer spending.

How large was the market in 2025?

Ken Research estimates the global veterinary healthcare market at USD 44,300 million in 2025. This is the report's base-year value and is repeated across the market summary, KPI information, and forecast discussion. North America is identified as the largest regional commercial hub, representing an estimated 39.0% of global revenue in 2025.

What is the 2031 market forecast and CAGR?

The market is projected to reach USD 63,555 million by 2031, implying a 6.2% CAGR during 2026-2031. The forecast combines treatment and diagnostic volume expansion with additional value from product mix, specialty therapies, biological products, diagnostics, inflation, and regulatory cost recovery. The published rate is consistent with the 2025 and 2031 values.

Which market segments matter most?

Product type is the dominant segmentation dimension, with therapeutics remaining the largest revenue pool. Technology is identified as the fastest-growing dimension, led by digital monitoring and precision delivery, while molecular diagnostics and biological products also support mix improvement. Commercially, the key shift is toward prevention, specialty care, and data-supported clinical workflows.

What is the primary opportunity and risk?

The primary opportunity is to capture recurring, higher-value demand in vaccination, chronic companion-animal treatment, rapid diagnostics, and connected monitoring. The main risk is execution: affordability constraints, disease volatility, antimicrobial controls, regulatory review, cold-chain reliability, and uneven veterinary access can slow adoption. Portfolios with narrow species or channel exposure are more vulnerable to disruption.

Methodology and Sources

Research Basis: Ken Research combined desk research on animal-health company filings, product approvals, disease surveillance, livestock and pet demand with primary interviews involving portfolio directors, chief veterinary officers, diagnostic laboratory leaders, and livestock procurement managers. Assumptions were triangulated against manufacturer, channel, volume, pricing, regional, and species evidence. Unverified material was omitted rather than inferred.

Sources: The primary source is the Global Veterinary Healthcare Market report. Official context was checked against the World Organisation for Animal Health 2025 report and FAO materials on antimicrobial resistance and surveillance.

Disclaimer: This article is for informational purposes and summarizes verified market evidence and analytical interpretation available from the cited sources. Forecasts are estimates rather than completed facts. Readers should consult the full report and relevant regulatory, veterinary, financial, or technical professionals before making investment, market-entry, clinical, procurement, or policy decisions.